We describe our recent achievements in the synthesis of chiral phosphorous ligands and their application in catalytic asymmetric hydrogenation reactions. Special attention is given to the development of novel binaphthophosphepine ligands. Starting from enantiomerically pure 1,1'-binaphthol or 2,2'-dimethyl-1,1'-binaphthyl and the building blocks A or B, new chelating Pligands have been synthesized in one step in good to excellent yields (68-95%). The resulting chiral bidentate phosphines, phosphites and phosphonites were tested in various asymmetric hydrogenation benchmark reactions. Interestingly, small structural changes within the ligands exhibit a significant influence on the enantioselectivity of the hydrogenation reactions.
Introduction
Catalysis, which is the science of accelerating chemical transformations, enables the chemical and pharmaceutical industry to offer a wide range of products for our health, environment, and nutrition. This makes catalysts indispensable for the needs of today's society and important tools for increasing sustainability. Catalysts are mainly used for environmental protection, the production of bulk and fine chemicals, oil processing in refineries, and polymer synthesis.
For some years our main area of scientific interest has been applied homogeneous catalysis with organometallic complexes. A key issue for controlling the activity, productivity, and selectivity of a given transition metal complex is the synthesis of molecularly defined catalytic centers. In other words, the electronic and steric properties of each active center can be controlled by using organic ligands, which coordinate to the metal center. Thus, "ligandtailoring" constitutes an extremely powerful tool to control all kinds of selectivity for a desired catalytic reaction and to influence catalyst stability and activity. Due to the advancements in organometallic chemistry and organic ligand synthesis, nowadays a plethora of ligands [P-, N-, and recently C-based ligands) is theoretically available (>>100.000). A selection of ligands recently developed in our laboratory is shown in Scheme 1. Apart from new aryl and alkyl phosphines 1-4, 1 For more than a decade the development of synthetic methods and the application of catalysis for the preparation of biologically active compounds have attracted our interest ( Figure 1 ). In this respect palladium-catalysis 4 and amination reactions 5 have been particularly investigated over the years. 6a   6b   6c   6j   6e  6f  6g   6h   6i   6d   6k   6l   6m   6n  6o  6p   66 Scheme 2. Ligand library of 4,5-dihydro-3H-dinaphtho[2,1-c;1',2'-e]phosphepines 6.
Typically, our aryl-substituted monodentate ligands gave enantioselectivities of 90-95% in standard benchmark asymmetric hydrogenations. Recently, in order to improve the enantioselectivity further, we considered the synthesis of bidentate 4,5-dihydro-3H-dinaphtho[2,1-c;1',2'-e]phosphepines. 19 As building blocks for the novel bidentate ligands we All ligands with the exception of 9 have been synthesized in the S,S,S-and S,R,S-forms by using the S-and R-configuration of 1,1'-binaphthol and 2,2'-dimethyl-1,1'-binaphthyl bridge to identify the matched and the mismatched combinations ( Figure 2) .
Ligands (S,S,S)-7 and (S,R,S)-7 were easily prepared according to literature protocols.
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The diphosphonites 8 were obtained in good yield by reaction of the building block S-B with Sor R-binaphthol in the presence of 1.1 equiv. of triethylamine. The crude product was purified by recrystallization as the rhodium complex [Rh(cod)8]BF 4 . For the synthesis of the corresponding phosphonites 9 and phosphines 10 the two methyl groups of 2,2'-dimethyl-1,1'-binaphthyl were lithiated selectively to form dark violet crystals. 21 Subsequently, chlorides A or B are quenched with the dilithium salt to produce the corresponding chelating ligands in high yield. In summary, we have synthesized a small pool of chelating ligands by replacing oxygen against carbon, step by step, allowing us a systematic investigation of the structural influence on the catalytic behaviour. Prior to our work ligands 8-9 had not been prepared, while 7 and 10 had not been used for asymmetric hydrogenation reactions. The diphosphite (S,S,S)-7 was first disclosed by Pringle and co-workers, 22 who used a Ni(0) complex of 7 for the hydrocyanation of norbornene with acetone cyanohydrine, giving the corresponding product in up to 38% ee. Another application of (S,S,S)-7-Cu(OTf) 2 was reported by Chan et al. 20 for the conjugate addition of diethylzinc to enones, where enantioselectivities up to 90% were achieved. In addition, Bakos 23 and Chan 24 tested the diphosphites 7 in the asymmetric hydroformylation of styrene and vinyl acetate, respectively. Buchwald et al. used a cobalt complex in combination with 7 as catalyst for intramolecular asymmetric Pauson-Khand reactions to obtain cyclopentenones in up to 75% enantiomeric excess. 25 The conjugate addition of arylboronic acids to dehydroalanine derivatives has been successfully carried out (up to 72% ee) in the presence of (R,R,R)-7. 26 The synthesis of diphosphine 10 as a diastereomeric mixture is also known in the literature. 27 Further bidentate ligands bearing the phosphepine unit A connected by phenyl or ferrocenyl bridges are known from the elegant work of Zhang et al. as binaphane and f-binaphane.
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Our initial catalytic studies focused on the asymmetric hydrogenation of α-aminoacid derivatives and itaconic acid dimethyl ester. Typically, catalytic experiments were carried out with 1 mol% of the catalyst [Rh(cod)L]BF 4 which was prepared in situ from 0.01 mmol [Rh(cod) 2 ]BF 4 and 1.1 equiv. of ligands 7-10. Table 1 summarizes the results for the asymmetric hydrogenation of methyl α-acetamidocinnamate 11 in toluene and ethyl acetate. In general, the S,S,S-configured ligands produce higher enantioselectivity than the S,R,S-configured ones. This trend dramatically finds its expression for the phosphonites 8 ( Table 1 , entries 5 and 6) where (S,S,S)-8 gave 95% ee and (S,R,S)-8 led to the racemic mixture. Obviously the S,S,S-form of the ligand constitutes the matched-and the S,R,S-form the mis-matched case. However, both combinations of phosphepine 10 (S,S,S and S,R,S) hydrogenated methyl α-acetamidocinnamate 11 with moderate enantioselectivity (between 38% and 47%, Table 1 , entries 11-14). Regarding the catalyst activity, the (S,S,S)-ligands 8 and 10 gave full conversion for this substrate within less than 1 h. On the other hand, especially ligand 7 and 9 hydrogenate so slowly that the reaction was stopped after 24 hours. The best enantioselectivity (96% ee) was achieved in ethyl acetate by applying (S,S,S)-8 ( Table 1 , entry 7) which bears P-O bonds in the two sevenmembered rings, and P-C bonds in the bridge. Next, we investigated our ligand pool in the asymmetric hydrogenation of methyl α-acetamidoacrylate 13. Based on previous solvent optimization studies the reaction was carried out in toluene, toluene+SDS (sodium dodecylsulfonate), THF, and ethyl acetate. Selected results for compounds 7-10 are given in Table 2 . In agreement with the hydrogenation of methyl α-acetamidocinnamate 11 ligand (S,S,S)-8 led to the best result. Enantioselectivities between 97% and 98% respectively (Table 2, entries 5 and 7) are obtained, while the isomeric (S,R,S)-8 gave only the racemic product! These results clearly show the importance of the right combination of the different chiral elements within the ligand. With respect to activity, in most cases complete conversion was observed in reasonable times. It is noteworthy that, with the exception of ligands 8, the general predefinition of the matched and the mismatched combination of the R-and S-configured building blocks is not clear for the hydrogenation of methyl α-acetamidoacrylate 13. In the asymmetric hydrogenation of dimethyl itaconate only moderate enantioselectivities were achieved with all ligands. For example (S,S,S)-7 and (S,S,S)-8 gave 32% and 39% ee, respectively.
After exploring the catalytic potential of the ligands in the hydrogenation of amino-acid precursors we were interested in the behaviour of (S,S,S)-8 under different reaction conditions. Table 3 shows a comparison of the in situ catalyst and the isolated complex [Rh(cod)(S,S,S)-8]BF 4 . Both α-amino acid derivatives were hydrogenated in up to 98% ee within short time. Using the isolated complex the catalyst activity is improved. Especially for the in situ catalytic system the hydrogenations run slowly in the non-polar solvent toluene (Table 3 , entries 4 and 6). Contrary to our previous experience for asymmetric hydrogenation with monodentate ligands 16 the addition of SDS to toluene has no significant influence.
Finally, the bidentate phosphepine 10 was also tested in the ruthenium-catalyzed asymmetric hydrogenation of various β-ketoesters. Other ligands were not included in this study because of the hydrolysis of the P-O bonds under the reaction conditions. All catalytic experiments were performed with 1 mol% catalyst formed in situ from [Ru(cod)methylallyl 2 ]/HBr and 1 equiv. of ligand 10 in ethanol or methanol. The results obtained for the hydrogenation of different 1,3-diketoesters are summarized in Table 4 . In general, the β-hydroxyesters were obtained in good yield, although with low to mediocre enantioselectivity. The best result (78% ee) is observed for the phenyl-substituted ketoester (Table 4 , entry 8) using the phosphepine 10 in the S,R,Sconfiguration. 
Conclusions
In conclusion, we have synthesized a library of novel bidentate chiral ligands containing 4,5-dihydro-3H-dinaphtho[2,1-c;1',2'-e]phosphepine and binaphthol building blocks. These ligands can be synthesized easily from 2,2'-binaphthol and 2,2'-dimethylbinaphthol. One of the prepared ligands ((S,S,S)-8) can be used efficiently for the rhodium-catalyzed hydrogenation of α-amino acid precursors, and enantioselectivities up to 98% ee were achieved.
Experimental Section General procedure for ligand synthesis General procedure for the synthesis of 7 and 8 To 1 equiv. of 2,2'-binaphthol and 2 equiv. of NEt 3 in toluene were added 2 equiv. of building block A or B at 0°C. After stirring the mixture for 2 h at room temperature and filtration of the precipitate the solvent is evaporated. The crude product is crystallized from ethanol/hexane (1) or THF/hexane (2) . General procedure for the synthesis of 9 and 10 A suspension of 1 equiv. of the dilithium salt of 2,2'-dimethyl-1,1'-binaphthyl in toluene is added through a tube to 2 equiv. of building block A or B dissolved in toluene, over a period of 30-45 min. The color of the reaction mixture turned from dark violet to yellow. After stirring for 10 h, LiCl was filtered off under inert conditions and washed with toluene. The solvent was evaporated and the crude product purified by flash column chromatography in dry toluene. 
Selected data for (S,S,S)-

Catalytic experiments
Asymmetric hydrogenation of α-aminoacids 11 and 13. Hydrogenation was performed under normal pressure at 25°C. A mixture of 0.01 mmol [Rh(cod) 2 ]BF 4 , 0.01 mmol ligand 7-10 and 0.1 mmol methyl α-acetamidocinnamate 5 or methyl α-acetamidoacrylate 7 was stirred for 15 min in 15 mL solvent. The hydrogenation flask was flushed several times with hydrogen. The reaction was followed by a volumetric measurement at 25°C ± 0.5°C. The enantiomeric excess of 12 (Lipodex E, 150°C isotherm) and 14 (Chirasil Val, 120°C isotherm) were determined by GC. Asymmetric hydrogenation of β-ketoesters 15a-d. Catalytic hydrogenation experiments were carried out in a parallel autoclave (8x3 mL). In a typical experiment, the autoclave was charged with a mixture of 3.8x10 -3 mmol of catalyst [LRuBr 2 ] prepared in situ and 3.8x10 -1 mmol β-ketoester 15a-d in 2 mL methanol or ethanol under an argon stream. The autoclave's contents were stirred at 60 bar hydrogen pressure and 100°C for 16-24 h. The autoclave was cooled to room temperature and the hydrogen was released. The reaction mixture was filtered over silica gel and the enantiomeric excess determined by GC (Lipodex E) or HPLC (Chiracel OD-H). Most of the hydrogenation products have been previously described. Methyl 3-hydroxybutyrate (16a): GC (25 m Lipodex E) 95°C isothermal: t r (min) = 4.9 (S), 5.7 (R); methyl 3-hydroxyvalerate (16b): GC (25 m Lipodex E) 85°C isothermal: t r (min) = 10.9 (S), 11.6 (R); ethyl 3-hydroxy-4-chlorobutyrate (16c): GC (25 m Lipodex E) 95°C isothermal: t r (min) = 20.4 (R), 20.6 (S); Ethyl 3-hydroxy-3-phenylpropionate (16d): HPLC (Chiracel OD-H, hexane/ethanol = 95:5, 0.5 mL/min), t r (min) = 10.1 (S), 11.5 (R).
